A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by Regeneron have seen notable improvements in hearing, according to new data ...